CD8A and neoplasm: Furthermore, preclinical mouse model studies indicated that ADCs could upregulate PD-1 in CD8 T cells and PD-L1 in tumor cells/tumor-associated macrophages, along with increasing tumor-infiltrating lymphocytes, compared to drug controls (23).